Immune‐Related Adverse Events in the Setting of PD‐1/L1 Inhibitor Combination Therapy

In 2018, a multi‐disciplinary workshop was held at the Massachusetts General Hospital to discuss challenges in defining, diagnosing, and treating immune‐related adverse events (irAE), including those that occur in patients administered PD‐1/L1 inhibitor combination therapy. In this commentary, the w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Zubiri, Leyre, Allen, Ian M., Taylor, Martin S., Guidon, Amanda C., Chen, Steven T., Schoenfeld, Sara R., Neilan, Tomas G., Sise, Meghan E., Mooradian, Meghan J., Rubin, Krista M., Leaf, Rebecca Karp, Parikh, Aparna R., Faje, Alexander, Gainor, Justin F., Cohen, Justine V., Fintelmann, Florian J., Kohler, Minna J., Dougan, Michael, Reynolds, Kerry L.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2019
Assuntos:
Commentaries
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7066708/
https://ncbi.nlm.nih.gov/pubmed/32162817
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0883
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados